Latest News and Press Releases

Kymab Presents Poster Detailing Adaptive Phase 1/2 Clinical Trial for its KY1044 Anti-ICOS Program at ASCO 2019 Annual Meeting Clinical trial initiated in February 2019 in the U.S., MD Anderson...

Kymab Appoints Pharmaceutical Veteran Simon Sturge as Chief Executive Officer Cambridge, UK; April 8, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics,...

Kymab Announces Promising Results from Initial Clinical Study of New Antibody KY1005 for Treatment of Autoimmune Diseases Top-line Phase I data demonstrated favorable safety, pharmacokinetics and...

Kymab Announces Agreement to Evaluate KY1044, its Novel Antibody Targeting ICOS, and Anti-PD-L1 Immunotherapy for testing in Multiple Solid Tumors Phase I/II studies will evaluate Kymab’s lead...

Kymab to present data on its lead immuno-oncology antibody, demonstrating strong potential for inhibiting tumour growth Cambridge, UK, 8 November 2017: Kymab Group Limited ("Kymab"), a...

Kymab and Seattle Children's Research Institute publish impressive results using Kymab's KY1005 in a model of Acute Graft versus Host Disease (aGVHD) in Science Translational Medicine KY1005 in...

Kymab Announces Clinical Update on its promising new antibody KY1005 for treatment of autoimmune diseases The third dosing cohort has been completed and 24 patients have now been dosed. ...

Kymab appoints Dr Martin Nicklasson as Non-Executive Chair Cambridge, UK, 16 June 2017 - Kymab Group Limited ("Kymab"), a leading human monoclonal antibody biopharmaceutical group, announces the...